StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Prabhudas Lilladher

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byPrabhudas LilladherHorizon: NA (inferred 1 year)26 Oct 2026via Moneycontrol Broker Research

Entry₹1,310.9Inferred
Target₹1,350
Total upside +2.98% (call closed)
Stop lossNot given
Exit₹1,35029 Oct 2026, 12:10 pm
Target hit+2.98%0.00%upside left
Follow Prabhudas Lilladher for new calls(71% target hit, 430 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 21 active Long-term calls on DRREDDYSee 273 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 29 Oct 2026
16 supporting5 neutral12 opposing
Supports the BUY call (16)

2 advisors have active short-term BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·27 Oct · 2d ago

10 other SEBI-registered advisors have active long-term BUY calls on this stock, with 6 issued in the last 14 days

Advisor consensus · same horizon·26 Oct · 2d ago

Dr Reddy's Q2 Review: Brokerages Flag Margin Recovery As Key Growth Driver — Check Target Price, Potential Upside

NewsNdtv-Profit·26 Oct · 3d ago

(opens in new tab)

Dr Reddy's gets DGCI clearance for Zytorvi; Here's how company shares reacted

NewsCnbc-Tv18·21 Oct · 1w ago

(opens in new tab)

Dr. Reddy's received DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India.

NSE · Press Release·21 Oct · 1w ago

(opens in new tab)
Neutral / worth noting (5)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 1w ago

(opens in new tab)
Weighs against the BUY call (12)

6 other SEBI-registered advisors have active long-term SELL calls on this stock, with 2 issued in the last 14 days

Advisor consensus · same horizon·26 Oct · 3d ago

Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginally

NewsEt-Markets·23 Oct · 5d ago

(opens in new tab)

Dr Reddy’s Q2 Results: Net profit falls as lower Lenalidomide sales hit revenue; beats estimates

NewsCnbc-Tv18·23 Oct · 5d ago

(opens in new tab)

Dr. Reddy's reported Q2 FY27 consolidated revenue of Rs 86.7 billion (down 1.5% YoY) and profit after tax of Rs 9.25 billion (down 36% YoY), impacted by lower lenalidomide sales in North America.

NSE · Outcome of Board Meeting·23 Oct · 5d ago

(opens in new tab)

Dr. Reddy's FTO-11 Facility Receives Two USFDA Form 483 Observations

NewsGoogle News·9 Oct · 3w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Prabhudas Lilladher

Every call and its outcome